“tighter than a Tasmanian family reunion” hahah you’re a funny guy!
Ahem yeah I meant Q1 2019 but HC wouldn’t let my go back and change it. Yep I read the extensive Sprout8 report when it was first released.
IMO the biggest risks are competition (liquid biopsy is making big claims) and the risk that trials 6 & 7 don’t deliver. If we remain on schedule Colostat will hit market years before an equivalent liquid biopsy test is available. Based on all the previous work clinical trials should be successful and that’ll determine the value of this company. Let’s hope they hit a six in trial 6! I’d like to know their anticipated timeframe...
New Feature Announcement!
We’re excited to introduce the DealRoom portal, now live on site, providing users with exciting access to private equity opportunities for both pre-IPO and publicly listed companies.
See full details by selecting the new menu item named 'DealRoom' on our main menu bar or click below.
Stay ahead of the market, with HotCopper.